PAREXEL has entered an alliance with CHA Medical Group (CHA) aimed at enhancing early phase clinical development in Korea. The collaboration is designed to provide biopharmaceutical companies with services that leverage PAREXEL’s global clinical research and regulatory expertise with CHA’s experience conducting early phase studies in Korea. Korea represents a growing hub for drug development for early phase trials due to government investment in the industry and access to patients. Korea’s re...